EAACI Congress 2024
BackOAS-CT01 - Clinical trials on Asthma and Rhinitis
Saturday 01 Jun, 15:00 PM -
16:30 PM Valencia, Spain
Innovation Hub
Oral Abstract Session on Clinical Trials
15:00
The SQ HDM SLIT-tablet is effective and well-tolerated in children (5-11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis – results from a global phase III clinical trial
15:12
The SQ HDM SLIT-tablet is effective and well-tolerated in children (5-11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis with and without concomitant asthma – results from a global phase III clinical trial
15:24
Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study
15:36
Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study
15:48
Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients With Uncontrolled Moderate-to-Severe Asthma: The VESTIGE Trial
16:00
A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis
16:12
Randomized, double-blind, placebo-controlled trial in seasonal allergic rhinitis patients shows trafficking of Lacticaseibasillus rhamnosus GG from mouth to nose to induce local effects
